tbuckley/cabot-search huggingface dataset:
Contactless WiFi Sensing and Monitoring for Future Healthcare - Emerging Trends, Challenges, and Opportunities
Authors: Yao Ge, Ahmad Taha, Syed Aziz Shah, Kia Dashtipour, Shuyuan Zhu, Jonathan Cooper, Qammer H. Abbasi, Muhammad Ali Imran
Journal: IEEE Reviews in Biomedical Engineering (2022)

WiFi sensing has received recent and significant interest from academia, industry, healthcare professionals, and other caregivers (including family members) as a potential mechanism to monitor our aging population at a distance without deploying devices on users' bodies. In particular, these methods have the potential to detect critical events such as falls, sleep disturbances, wandering behavior, respiratory disorders, and abnormal cardiac activity experienced by vulnerable people. The interest in such WiFi-based sensing systems arises from practical advantages including its ease of operation indoors as well as ready compliance from monitored individuals. Unlike other sensing methods, such as wearables, camera-based imaging, and acoustic-based solutions, WiFi technology is easy to implement and unobtrusive. This paper reviews the current state-of-the-art research on collecting and analyzing channel state information extracted using ubiquitous WiFi signals, describing a range of healthcare applications and identifying a series of open research challenges, including untapped areas of research and related trends. This work aims to provide an overarching view in understanding the technology and discusses its use-cases from a perspective that considers hardware, advanced signal processing, and data acquisition.
Rapid Screening Using Pathomorphologic Interpretation to Detect <i>BRAF</i>V600E Mutation and Microsatellite Instability in Colorectal Cancer
Authors: Satoshi Fujii, Daisuke Kotani, Masahiro Hattori, Masato Nishihara, Toshihide Shikanai, Junji Hashimoto, Yuki Hama, Takuya Nishino, Mizuto Suzuki, Ayatoshi Yoshidumi, Makoto Ueno, Yoshito Komatsu, Toshiki Masuishi, Hiroki Hara, Taito Esaki, Yoshiaki Nakamura, Hideaki Bando, Tomoyuki Yamada, Takayuki Yoshino
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Rapid decision-making is essential in precision medicine for initiating molecular targeted therapy for patients with cancer. This study aimed to extract pathomorphologic features that enable the accurate prediction of genetic abnormalities in cancer from hematoxylin and eosin images using deep learning (DL). Experimental Design: A total of 1,657 images (one representative image per patient) of thin formalin-fixed, paraffin-embedded tissue sections from either primary or metastatic tumors with next-generation sequencing–confirmed genetic abnormalities—including BRAFV600E and KRAS mutations, and microsatellite instability high (MSI-H)—that are directly relevant to therapeutic strategies for advanced colorectal cancer were obtained from the nationwide SCRUM-Japan GI-SCREEN project. The images were divided into three groups of 986, 248, and 423 images to create one training and two validation cohorts, respectively. Pathomorphologic feature-prediction DL models were first developed on the basis of pathomorphologic features. Subsequently, gene-prediction DL models were constructed for all possible combinations of pathomorphologic features that enabled the prediction of gene abnormalities based on images filtered by the combination of pathomorphologic feature-prediction models. Results: High accuracies were achieved, with AUCs &amp;gt; 0.90 and 0.80 for 12 and 27, respectively, of 33 analyzed pathomorphologic features, with high AUCs being yielded for both BRAFV600E (0.851 and 0.859) and MSI-H (0.923 and 0.862). Conclusions: These findings show that novel next-generation pathology methods can predict genetic abnormalities without the need for standard-of-care gene tests, and this novel next-generation pathology method can be applied for colorectal cancer treatment planning in the near future.
Extramedullary disease in multiple myeloma: a systematic literature review
Authors: Joan Bladé, Meral Beksac, Jo Caers, Artur Jurczyszyn, Marie von Lilienfeld-Toal, Philippe Moreau, Leo Rasche, Laura Rosiñol, Saad Z. Usmani, Elena Zamagni, Paul Richardson
Journal: Blood Cancer Journal (2022)

Abstract Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. Several different definitions of EMD have been used in the published literature. We advocate that true EMD is restricted to soft-tissue plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD vary according to the phase of MM. At diagnosis, EMD is typically found in skin and soft tissues; at relapse, typical sites involved include liver, kidneys, lymph nodes, central nervous system (CNS), breast, pleura, and pericardium. The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with newly diagnosed MM, the reported incidence ranges from 0.5% to 4.8%, while in relapsed/refractory MM the reported incidence is 3.4 to 14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without soft-tissue plasmacytomas. Among patients with plasmacytomas, those with EMD have poorer outcomes than those with paraskeletal involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement. Available data on treatment outcomes for EMD are derived almost entirely from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected, this is less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes.
EFFICACY AND SAFETY OF LOW DOSE COLCHICINE ON SURROGATE MARKERS OF CARDIOVASCULAR EVENTS IN PEOPLE LIVING WITH HIV RECEIVING ANTIRETROVIRAL THERAPY
Authors: Theerawat Korkerdsup, Angsana Phuphuakrat, Somnuek Sungkanuparph, Krissada Meemook
Journal: Journal of the American College of Cardiology (2022)
IMPACT OF POOR MENTAL HEALTH ON CARDIOVASCULAR MORTALITY IN UNITED STATES: COUNTY LEVEL ANALYSIS FROM 2010 TO 2019
Authors: Shady Abohashem, Ahmed Sayed, Rehab Salah, Hazem S. Ghaith, Wesam Aldosoky, Tanveer Mir, Taimur Abbasi, Tawseef Dar
Journal: Journal of the American College of Cardiology (2022)
CONTEMPORARY MANAGEMENT AND CLINICAL OUTCOMES OF PATIENTS WITH LEFT MAIN CORONARY ARTERY ST ELEVATION MYOCARDIAL INFARCTION: AN ANALYSIS OF THE NATIONAL INPATIENT SAMPLE
Authors: Emily Hiltner, Ossama Elsaid, Ashish Awasthi, John Kassotis, Abdul Hakeem, Ankur Sethi
Journal: Journal of the American College of Cardiology (2022)
Striking the Right Balance With Prostate Cancer Screening
Authors: Richard M. Hoffman
Journal: JAMA Network Open (2022)

Mihir M. Desai, MD, MPH; Giovanni E. Cacciamani, MSc, MD; Karanvir Gill, MS; Juanjuan Zhang, PhD; Lihua Liu, PhD; Andre Abreu, MD; Inderbir S. Gill, MD, MCh
OUTCOMES OF CARDIAC SURGERY WITH LEFT ATRIAL APPENDAGE OCCLUSION VERSUS NO OCCLUSION, DIRECT ORAL ANTICOAGULANTS, AND VITAMIN K ANTAGONISTS
Authors: Nso Nso, Mahmoud Nassar, Sofia Lakhdar, Tanveer Shaukat, Laura Guzman, Rubal Bhangal, Mohsen Alshamam, Vincent Vincent Rizzo, Most Sirajum Munira, Farshid Radparvar, Senthil Thambidorai
Journal: Journal of the American College of Cardiology (2022)
Table of contents
Authors: Rebecca Quiñonez, Oma Agbai, Cheryl Burgess, Susan Taylor, Dirk Elston, Steven Sloan, Jonathan Kantor, Kylee Kus, Fadi Murad, Timothy Smile, Michael Chang, Sepideh Ashrafzadeh, Guohai Zhou, Evelyn Ilori, Shlomo Koyfman, Allison Vidimos, Chrysalyne Schmults, Emily Ruiz, Enzo Errichetti, Shamir Geller, Iris Zalaudek, Caterina Longo, Athanassios Kyrgidis, Nisa Akay, Vincenzo Piccolo, Patricia Myskowski, Paola Vitiello, Teresa Russo, Giuseppe Argenziano, Martyna S1awi Nska, Ma1gorzata Soko1owska-Wojdy1o, Jurakic Toncic, Jaka Rados, Daniela Ledic Drvar, Romana Ceovic, Gra_ Zyna Kaminska-Winciorek, Pedro Zaballos, Camilla Reggiani, Zorana Kremic, Sven Lanssens, Ayse T€, Ulin G€ Ulec ¸, Alejandro Lobato-Berezo, Giovanni Damiani, Vincenzo Maione, Piergiacomo Calzavara-Pinton, Elena Sotiriou, Giuseppe Stinco, Zoe Apalla, Aimilios Lallas, Joel Dekoven, Benjamin Dekoven, Erin Warshaw, C Mathias, James Taylor, Denis Sasseville, Donald Belsito, Joseph Fowler, Melanie Pratt, Kathryn Zug, Howard Maibach, Vincent Deleo, Jonathan Silverberg, Amber Atwater, Margo Reeder, D Linn Holness, Chryssoula Papageorgiou, Sofia Manoli, Michela Lai, Konstantinos Liopyris, Konstantinos Lallas, Elizabeth Lazaridou, Adrian Joseph, Michel Bailey, Heidi Oi-, Yee Li, Marcus Tan, Wei Cheng, Jeffrey Dover, Yasmin Chia, Chia Liew, Karen Jui, Lin Choo, Chiat Oh, Ming Pang, Yi Dermatology, Yueh Dermatology, Jessica Labadie, Emily Poon, Murad Alam, Jason Yang, Kevin Nguyen, Michael Fleischman, Omar Aly, Kyle Cheng, Leah Thompson, Nicole Polyakov, Amy Blum, Nathaniel Josephs, Nira Krasnow, Jaewon Yoon, Edward Li, Gabriel Molina, Jordan Said, Kevin Huang, Juhi Kuchroo, Andrea Hinton, Steven Chen, Tarek Nawar, Khaled Elsayad, Elisa M€ Uller, Daniel Rolf, Rose Moritz, Eike Bormann, Carsten Weishaupt, Rene ´stranzenbach, Rudolf Stadler, Christos Moustakis, Chalid Assaf, Elisabeth Livingstone, Kerstin Steinbrink, Hans Eich, Kevin Severson, Meera Patel, Caitlin Brumfiel, Ilana Breen, Richard Butterfield, Steven Nelson, Aleksander Sekulic, Mark Pittelkow, Aaron Mangold, Delila Foulad, Joshua Fouladian, Aaron Amir, Natasha Hakimi, Jeffrey Liu, Akshitha Thatiparthi, Amylee Martin, Jashin Wu, Asfandyar Mufti, Nadia Kashetsky, Abrahim Abduelmula, Yuliya Bscn, Jensen Lytvyn, Philippe Yeung, Pingxing Xie, Khue Nguyen
Journal: Journal of the American Academy of Dermatology (2022)
Trends in Prediabetes Among Youths in the US From 1999 Through 2018
Authors: Junting Liu, Yan Li, Donglan Zhang, Stella S. Yi, Junxiu Liu
Journal: JAMA Pediatrics (2022)

The US Preventive Services Task Force recently released a recommendation on screening for prediabetes and type 2 diabetes among adults, 1 but no recommendation has been issued for youths to date.A recent study 2 estimated that among youths aged 12 to 19 years, approximately 1 in 5 had prediabetes, with large variations across sociodemographic characteristics.However, trends in the prevalence of prediabetes among youths and associated disparities by population subgroups over the past 2 decades have not been reported to our knowledge, and such information is important for future diabetes prevention.In this study, we assessed trends in prediabetes among US youths from 1999 through 2018.Methods | This survey study used data from 10 cycles of the National Health and Nutrition Examination Survey (NHANES) from 1999-2000 through 2017-2018 and combined every 2 consecutive cycles to obtain sufficient sample sizes.We included youths aged 12 to 19 years who completed the interview and examination.NHANES is a series of cross-sectional surveys using a complex, multistage probability design to sample the civilian, noninstitutionalized population.The NHANES protocol was approved by the US Centers for Disease Control and Prevention National Center for Health Statistics Ethics Review Board, and all participants provided written informed consent, or assent was obtained from participants or their guardians, respectively.This study was exempt from the Mount Sinai institutional review board review because it used publicly deidentified data sets.Details on NHANES survey methods and analytic methods are documented elsewhere. 3This study followed the American Association for Public Opinion Research (AAPOR) reporting guideline.Sociodemographic variables included sex, age, race and ethnicity (Hispanic, non-Hispanic Asian, non-Hispanic Black, and non-Hispanic White), parental educational level (less than high school, high school, and some college and above), income level (family income to poverty ratio <1.3, 1.3 to <3.0, and
Abstract P4-05-11: The clinical importance of the new category, ER low-positive in the ER expression HER2 negative early breast cancer
Authors: Tajiri Wakako
Journal: Cancer Research (2022)

Abstract &amp;lt;Background&amp;gt;In the latest updated ASCO/CAP guideline, a new category, ER low-positive was introduced, which are determined by the 1% to10 % of positive staining of the tumor nuclei for ER. However clinical meaning of ER-low positive was unclear compared with ER- positive or ER-negative in HER2 negative breast cancer. &amp;lt;Purpose&amp;gt; In order to clarify the clinicopathological features of ER-low positive breast cancer, we compared the clinicopathological factors and prognosis among three groups, ER negative, ER-low positive, and ER-positive groups in the patients with HER2 negative breast cancer. &amp;lt;Patients and Method&amp;gt; A total of 1,882 patients with HER2 negative breast cancer who underwent surgery between 2001 and 2018 were included in this study. We divided them into three groups, ER negative (&amp;lt;1%), ER-low positive (1-10%), and ER positive (10%≦). The relationships between ER status and clinicopathological characteristics and prognosis were evaluated. &amp;lt;Result&amp;gt;According to ER status, 553(29.4%), 183(9.7%), 1146(60.9%) patients were divided into ER negative, low-positive and positive groups. Compared with ER-positive group, patients in the ER negative and low-positive groups were of higher age (p&amp;lt;.0001), and those tumors were significantly associated with the larger tumor size (p&amp;lt;.0001), higher histological grade (p&amp;lt;.0001) and more administration of adjuvant chemotherapy (p&amp;lt;0.0001). Most of the patients with ER low-positive and ER-positive tumors had received the adjuvant endocrine therapy. The prognosis of the patients with ER low-positive tumors were poorer than that of those with ER positive tumors in terms of relapse-free survival (RFS p&amp;lt;.0001), distant metastasis-free survival (DMFS p&amp;lt;.0001) and overall survival (OS p&amp;lt;.0001).In the node negative patients, the prognosis of the ER-negative and ER low-positive groups were equivalent, and poorer than that of the ER-positive group (RFS; p=0.0068, DMFS; p=0.0013, OS: p=0.0032). In addition, in pStage III patients, prognosis of the ER-negative and ER low-positive groups were also equivalent, and poorer than that of the ER-positive group (RFS; p=0.008, DMFS; p=0.0021, OS: p=0.0010). &amp;lt;Conclusion&amp;gt; This study showed that the prognosis of the patients with ER negative and ER low-positive were similar, and poorer than that of those with ER positive tumors. Therefore, the new category of ER-low positive is clinically especially important in order to determine the appropriate adjuvant therapy. Citation Format: Tajiri Wakako. The clinical importance of the new category, ER low-positive in the ER expression HER2 negative early breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-05-11.
Abstract P4-01-04: FGFR inhibitor mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces therapeutic resistance in triple negative breast cancer
Authors: Yihao Li, Xintao Qiu, Xiaoqing Wang, Hui Liu, Renee Geck Geck, Alok Tewari, Kin-Hoe Chow, Tengfei Xiao, Paloma Cejas, Quang-Dé Nguyen, Henry Long, Shirley X Liu, Alex Toker, Myles Brown
Journal: Cancer Research (2022)

Abstract How cancer cells adapt to evade the therapeutic effects of drugs targeting oncogenic drivers is poorly understood. Here we report an epigenetic mechanism leading to the adaptive resistance of triple-negative breast cancer (TNBC) to fibroblast growth factor receptor (FGFR) inhibitors. Prolonged FGFR inhibition suppresses the function of BRG1-dependent chromatin remodeling leading to an epigenetic state that derepresses YAP-associated enhancers. These chromatin changes induce the expression of several amino acid transporters resulting in increased intracellular levels of specific amino acids that reactivate mTORC1. Consistent with this mechanism, addition of mTORC1 or YAP inhibitors to FGFR blockade synergistically attenuated the growth of TNBC patient-derived xenografts (PDX) models. Collectively, these findings reveal a novel feedback loop involving an epigenetic state transition and metabolic reprogramming that leads to adaptive therapeutic resistance and provide new therapeutic strategies to overcome this mechanism of resistance. Citation Format: Yihao Li, Xintao Qiu, Xiaoqing Wang, Hui Liu, Renee Geck Geck, Alok Tewari, Kin-Hoe Chow, Tengfei Xiao, Paloma Cejas, Quang-Dé Nguyen, Henry Long, Shirley X Liu, Alex Toker, Myles Brown. FGFR inhibitor mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces therapeutic resistance in triple negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-01-04.
A RARE CASE OF PERFORATION AT THE LEVEL OF ANNULUS FIBROSA IN A PATIENT WITH SEVERE ECCENTRIC AORTIC VALVE REGURGITATION
Authors: Bandar Alyami, Kesavan Sankaramnagalam, Mathew Shotwell, Sameer Raina, Bryan D. Raybuck, Vikrant Jagadesan, Yasmin Hamirani
Journal: Journal of the American College of Cardiology (2022)
SUSPECTED FABRY'S DISEASE AND ITS IMPACT ON CLINICAL EVOLUTION: APPROACH BY A MULTIDISCIPLINARY TEAM
Authors: Nicolas Federico Renna, Eliel Ramirez, Franco Matar, Pablo Bernasconi, Martin Repetto, Romina Zalazar, Marcia Zuloaga, Jesica Ramirez
Journal: Journal of the American College of Cardiology (2022)
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC
Authors: Chupeng Hu, Bingqing Xu, Xiaodong Wang, Wen‐Hua Wan, Jinying Lu, Deyuan Kong, Yu Jin, Wenhua You, Hua Sun, Xiaoxin Mu, Dongju Feng, Yun Chen
Journal: Hepatology (2022)

Background and Aims: Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3 regulation. Approach and Results: We report that Lactobacillus reuteri was markedly reduced in the gut microbiota of mice with HCC, accompanied by decreased SCFA levels, especially acetate. Additionally, transplantation of fecal bacteria from wild‐type mice or L. reuteri could promote an anticancer effect, elevate acetate levels, and reduce IL‐17A secretion in mice with HCC. Mechanistically, acetate reduced the production of IL‐17A in hepatic ILC3s by inhibiting histone deacetylase activity, increasing the acetylation of SRY (sex‐determining region Y)‐box transcription factor 13 (Sox13) at site K30, and decreasing expression of Sox13. Moreover, the combination of acetate with programmed death 1/programmed death ligand 1 blockade significantly enhanced antitumor immunity. Consistently, tumor‐infiltrating ILC3s correlated with negative prognosis in patients with HCC, which could be functionally mediated by acetate. Conclusions: These findings suggested that modifying bacteria, changing SCFAs, reducing IL‐17A‐producing ILC3 infiltration, and combining with immune checkpoint inhibitors will contribute to the clinical treatment of HCC.
Studies on activation and regulation of the coagulation cascade in chronic rhinosinusitis with nasal polyps
Authors: Ping-Ping Cao, Bao-Feng Wang, James E. Norton, Lydia A. Suh, Roderick G. Carter, Whitney W. Stevens, Anna G. Staudacher, Julia H. Huang, Kathryn E. Hulse, Anju T. Peters, Leslie C. Grammer, David B. Conley, Kevin C. Welch, Robert C. Kern, Zheng Liu, Jingying Ye, Robert P. Schleimer
Journal: Journal of Allergy and Clinical Immunology (2022)
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply
Authors: Hwa Kyung Byun, Yong Bae Kim, Chang-Ok Suh
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
INCIDENTALLY DIAGNOISED LARGE RIGHT VENTRICULAR PSEUDOANEURYSM IN PATIENT WITH REMOTE HISTORY OF TRAUMA
Authors: Kalpeshkumar Shah, Muhammad Atif Masood Noori, Hardik Fichadiya, Biren D. Patel, Nirmal Guragai, Dhaval Shah, Meherwan Joshi, Fayez E. Shamoon
Journal: Journal of the American College of Cardiology (2022)
Climate emergency: how should COP27 do better for adolescents and young people?
Authors: Giulia Gasparri, Mohamed Eissa, David Imbago-Jácome, Bhavya Nandini
Journal: BMJ (2022)

With COP27 due to be held in November 2022, these young authors discuss why it must be more inclusive, with representation from the global south, and with young people engaged in a more meaningful way
CCL7 and TGF-β secreted by MSCs play opposite roles in regulating CRC metastasis in a KLF5/CXCL5-dependent manner
Authors: Zhuoqing Xu, Han Gao, Yuchen Zhang, Wenqing Feng, Yiming Miao, Zifeng Xu, Wenchang Li, Fangqian Chen, Zeping Lv, Jianting Huo, Wangyi Liu, Xiaohui Shen, Yaping Zong, Jingkun Zhao, Aiguo Lu
Journal: Molecular Therapy (2022)

CXCL5 is overexpressed in colorectal cancer (CRC) and promotes distant metastasis and angiogenesis of tumors; however, the underlying mechanism that mediates CXCL5 overexpression in CRC remains unclear. Here, we successfully extracted and identified primary mesenchymal stromal cells (MSCs) and verified the promoting effects of tumor-associated MSCs on CRC proliferation and metastasis in vivo and in vitro. We found that MSCs not only promoted the expression of CXCL5 by secreting CCL7 but also secreted TGF-β to inhibit this process. After secretion, CCL7/CCR1 activated downstream CBP/P300 to acetylate KLF5 to promote CXCL5 transcription, while TGF-β reversed the effect of KLF5 on transcription activation by regulating SMAD4. Taken together, our results indicate that MSCs in the tumor microenvironment promoted the progression and metastasis of CRC and regulated the expression of CXCL5 in CRC cells by secreting CCL7 and TGF-β. KLF5 is the key site of these processes and plays a dual role in CXCL5 regulation. MSCs and their secreted factors may serve as potential therapeutic targets in the tumor environment.